Folic acid/oral contraceptives
Executive Summary
FDA's Reproductive Health Drugs Advisory Committee will discuss the potential benefits of combining folic acid and oral contraceptives into a single product at a Dec. 15 meeting. Oral contraceptives are known to reduce the levels of folic acid, and reduced folic acid levels have been associated with neural tube defects in newborns. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...
You may also be interested in...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: